32 related articles for article (PubMed ID: 19520690)
1. Efficacy of ranibizumab combined with photodynamic therapy on wet age-related macular degeneration.
Chen L; Wang B; Cui W; Fang S
Exp Ther Med; 2020 Jun; 19(6):3691-3697. PubMed ID: 32346433
[TBL] [Abstract][Full Text] [Related]
2. Negative Regulators of Angiogenesis, Ocular Vascular Homeostasis, and Pathogenesis and Treatment of Exudative AMD.
Farnoodian M; Sorenson CM; Sheibani N
J Ophthalmic Vis Res; 2018; 13(4):470-486. PubMed ID: 30479719
[TBL] [Abstract][Full Text] [Related]
3. Combination of bevacizumab and photodynamic therapy vs. bevacizumab monotherapy for the treatment of wet age-related macular degeneration: A meta-analysis of randomized controlled trials.
Wei Q; Liu J; Liu Q; Ren C; Cai W; Liang X; Wen J; Yu J
Exp Ther Med; 2018 Aug; 16(2):1187-1194. PubMed ID: 30116368
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
5. Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial.
Gallemore RP; Wallsh J; Hudson HL; Ho AC; Chace R; Pearlman J
Clin Ophthalmol; 2017; 11():223-231. PubMed ID: 28182161
[TBL] [Abstract][Full Text] [Related]
6. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia.
Rinaldi M; Semeraro F; Chiosi F; Russo A; Romano MR; Savastano MC; dell'Omo R; Costagliola C
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):529-539. PubMed ID: 27680013
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.
Mikačić I; Bosnar D
Drug Saf; 2016 Jun; 39(6):517-41. PubMed ID: 26951234
[TBL] [Abstract][Full Text] [Related]
8. Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration.
Weingessel B; Mihaltz K; Vécsei-Marlovits PV
Wien Klin Wochenschr; 2016 Aug; 128(15-16):560-5. PubMed ID: 25787216
[TBL] [Abstract][Full Text] [Related]
9. Polypoidal choroidal vasculopathy: an update on therapeutic approaches.
Wong RL; Lai TY
J Ophthalmic Vis Res; 2013 Oct; 8(4):359-71. PubMed ID: 24653824
[TBL] [Abstract][Full Text] [Related]
10. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Yoshida Y; Kohno T; Yamamoto M; Yoneda T; Iwami H; Shiraki K
Jpn J Ophthalmol; 2013 May; 57(3):283-93. PubMed ID: 23413039
[TBL] [Abstract][Full Text] [Related]
11. Oscillatory photodynamic therapy for choroidal neovascularization and central serous retinopathy; a pilot study.
Peyman GA; Tsipursky M; Nassiri N; Conway M
J Ophthalmic Vis Res; 2011 Jul; 6(3):166-76. PubMed ID: 22454731
[TBL] [Abstract][Full Text] [Related]
12. The past, present, and future of exudative age-related macular degeneration treatment.
Barak Y; Heroman WJ; Tezel TH
Middle East Afr J Ophthalmol; 2012 Jan; 19(1):43-51. PubMed ID: 22346114
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
Weigert G; Michels S; Sacu S; Varga A; Prager F; Geitzenauer W; Schmidt-Erfurth U
Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
[TBL] [Abstract][Full Text] [Related]
15. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
[TBL] [Abstract][Full Text] [Related]
16. Age-related macular degeneration.
Jager RD; Mieler WF; Miller JW
N Engl J Med; 2008 Jun; 358(24):2606-17. PubMed ID: 18550876
[No Abstract] [Full Text] [Related]
17. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration.
Regillo CD; D'Amico DJ; Mieler WF; Schneebaum C; Beasley CH; Sullins GT
Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S70-8. PubMed ID: 17240259
[TBL] [Abstract][Full Text] [Related]
18. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study.
Potter MJ; Claudio CC; Szabo SM
Br J Ophthalmol; 2010 Feb; 94(2):174-9. PubMed ID: 19520690
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
